Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients

Cellular Immunology

Volumn 297, Issue 2, 2015, Pages 87-93

  Gong, Nianqiao ^a   Chen, Zhishui ^a   Wang, Jing ^a   Fang, Aifang ^a   Li, Yonghai ^a   Xiang, Ying ^a   Ming, Changsheng ^a   Zhang, Weijie ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Kidney transplantation; Regulatory T cells; Sirolimus; Tacrolimus

Indexed keywords

CD19 ANTIGEN; CD1D ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CREATININE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLATE MOFETIL; PANEL REACTIVE ANTIBODY; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CELL POLARITY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE STATUS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM SURVIVAL; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH2 CELL; ALLOGRAFT; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; TIME FACTOR;

ADULT; ALLOGRAFTS; B-LYMPHOCYTES, REGULATORY; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TACROLIMUS; TH1 CELLS; TH2 CELLS; TIME FACTORS;

EID: 84945474291     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.07.002     Document Type: Article

References (30)

1. de Mattos A.M., Olyaei A.J., Bennett W.M. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am. J. Kidney Dis. 2000, 35:333-346.
2. Olyaei A.J., de Mattos A.M., Bennett W.M. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr. Opin. Crit. Care 2001, 7:384-389.
3. Gutierrez-Dalmau A., Campistol J.M. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007, 67:1167-1198.
4. Morales J.M., Wramner L., Kreis H., Durand D., Campistol J.M., Andres A., Arenas J., Negre E., Burke J.T., Groth C.G. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am. J. Transplant. 2002, 2:436-442.
5. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol. Today 1992, 13:136-142.
6. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 2004, 16:564-575.
7. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883-889.
8. Geissler E.K., Schlitt H.J. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int. 2010, 78:1075-1079.
9. Wu T., Zhang L., Xu K., Sun C., Lei T., Peng J., Liu G., Wang R., Zhao Y. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo. Transpl. Immunol. 2012, 27:30-38.
10. Lu L., Qian X.F., Rao J.H., Wang X.H., Zheng S.G., Zhang F. Rapamycin promotes the expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation. Transplant. Proc. 2010, 42:1755-1757.
11. San Segundo D., Fabrega E., Lopez-Hoyos M., Pons F. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors. Transplant. Proc. 2007, 39:2290-2292.
12. Segundo D.S., Ruiz J.C., Izquierdo M., Fernandez-Fresnedo G., Gomez-Alamillo C., Merino R., Benito M.J., Cacho E., Rodrigo E., Palomar R., Lopez-Hoyos M., Arias M. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006, 82:550-557.
13. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
14. Battaglia M., Stabilini A., Migliavacca B., Horejs-Hoeck J., Kaupper T., Roncarolo M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 2006, 177:8338-8347.
15. Chu Z.Q., Ji Q. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients. Transplant. Proc. 2013, 45:153-156.
16. Hackstein H., Taner T., Zahorchak A.F., Morelli A.E., Logar A.J., Gessner A., Thomson A.W. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101:4457-4463.
17. Turnquist H.R., Raimondi G., Zahorchak A.F., Fischer R.T., Wang Z., Thomson A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 2007, 178:7018-7031.
18. Taner T., Hackstein H., Wang Z., Morelli A.E., Thomson A.W. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am. J. Transplant. 2005, 5:228-236.
19. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
20. Chesneau M., Michel L., Degauque N., Brouard S. Regulatory B cells and tolerance in transplantation: from animal models to human. Front. Immunol. 2013, 4:497.
21. Newell K.A., Phippard D., Turka L.A. Regulatory cells and cell signatures in clinical transplantation tolerance. Curr. Opin. Immunol. 2011, 23:655-659.
22. Gao W., Lu Y., El Essawy B., Oukka M., Kuchroo V.K., Strom T.B. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am. J. Transplant. 2007, 7:1722-1732.
23. de la Rosa M., Rutz S., Dorninger H., Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 2004, 34:2480-2488.
24. Levitsky J., Mathew J.M., Abecassis M., Tambur A., Leventhal J., Chandrasekaran D., Herrera N., Al-Saden P., Gallon L., Abdul-Nabi A., Yang G.Y., Kurian S.M., Salomon D.R., Miller J. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology 2013, 57:239-248.
25. Levitsky J., Gallon L., Miller J., Tambur A.R., Leventhal J., Flaa C., Huang X., Sarraj B., Wang E., Mathew J.M. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation 2011, 91:199-206.
26. Lee K.M., Stott R.T., Zhao G., SooHoo J., Xiong W., Lian M.M., Fitzgerald L., Shi S., Akrawi E., Lei J., Deng S., Yeh H., Markmann J.F., Kim J.I. TGF-beta-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur. J. Immunol. 2014, 44:1728-1736.
27. Yanaba K., Bouaziz J.D., Haas K.M., Poe J.C., Fujimoto M., Tedder T.F. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
28. Guo H., Qiao Z., Zhu L., Wang H., Su L., Lu Y., Cui Y., Jiang B., Zhu Q., Xu L. Th1/Th2 cytokine profiles and their relationship to clinical features in patients following nonmyeloablative allogeneic stem cell transplantation. Am. J. Hematol. 2004, 75:78-83.
29. Foley J.E., Jung U., Miera A., Borenstein T., Mariotti J., Eckhaus M., Bierer B.E., Fowler D.H. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J. Immunol. 2005, 175:5732-5743.
30. Arias-Diaz J., Ildefonso J.A., Munoz J.J., Zapata A., Jimenez E. Both tacrolimus and sirolimus decrease Th1/Th2 ratio, and increase regulatory T lymphocytes in the liver after ischemia/reperfusion. Lab. Invest. 2009, 89:433-445.